Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2024-02-08 Interest Rate Update/No…
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interest Rate Update/Notice Classification · 95% confidence The document is a brief filing providing an updated calculation of the earnings coverage ratio for the 12 months ended December 31, 2023. It references compliance with a regulatory instrument related to a medium-term note program and includes specific financial figures related to borrowing costs and net income. The document is short (1044 characters) and focuses on a specific financial metric related to debt servicing rather than presenting a full financial report or earnings release. It does not contain comprehensive financial statements or detailed quarterly results. This type of update on borrowing cost coverage aligns best with an Interest Rate Update/Notice (IRAT) as it pertains to debt and borrowing costs information rather than a full earnings release or annual report.
2024-02-08 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Medexus Announces Fiscal Q3 2024 Results' and contains detailed financial data including revenue, operating income, adjusted EBITDA, net loss, and cash flow for the three- and nine-month periods ended December 31, 2023. It discusses operational highlights, product pipeline updates, and management commentary on business conditions and cost reduction initiatives. The presence of comprehensive financial results and analysis for a fiscal quarter indicates this is a quarterly financial report. The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-02-08 English
News release - English.pdf
Regulatory Filings
2024-01-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Health Canada has accepted for review Medexus's New Drug Submission (NDS) for a topical terbinafine product. It discusses regulatory review status, potential market entry, and forward-looking statements about the product launch. There are no financial statements, earnings data, or detailed financial analysis. The document is an update on regulatory progress and product development rather than a financial report or detailed investor presentation. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or legal proceeding. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a new drug submission review by Health Canada, which does not fit into more specific categories like earnings release, capital update, or management report.
2024-01-08 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Medexus Pharmaceuticals' fiscal Q2 2024 financial results, including revenue, EBITDA, net loss, liquidity, and operational highlights. It also provides management commentary, product pipeline updates, and details about a conference call to discuss these results. The document contains substantive financial data and analysis for the quarter ended September 30, 2023, which is a fiscal quarter. The presence of detailed financial metrics, operational performance, and management discussion indicates this is a comprehensive interim financial report. It is not merely an earnings release (which would be shorter and less detailed), nor is it a call transcript (though it announces a call), nor a report publication announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2023-11-09 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO of Medexus Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2023. The content is primarily an officer certification regarding the interim filings, controls, and procedures, without containing actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3416 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2023-11-09 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.